HomeDealsNegotiationsPolicyPipelineMoneyPeopleDataThe WeekPharmTech 100Deal TrackerResearch
Pipeline

STAT+: AACR 2026: More strong data for Revolution Medicines’ KRAS drug

You're reading the web version of STAT's popup newsletter, AACR in 30 seconds, your guide to what's happening at the American Association of Cancer Researchers' annual meeting. Sign up here.We’re…

By STAT News · Apr 19, 2026 · via STAT News
STAT+: AACR 2026: More strong data for Revolution Medicines’ KRAS drug

Image: STAT News

This is an aggregated industry headline. Read the full story at STAT News →

Tags
pipelineformat:headlineheadlineSTAT News
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.
More from Pipeline
All Pipeline →
With Voxzogo under pressure, BioMarin touts trial win in label expansion bid
PipelineFiercePharma ↗
With Voxzogo under pressure, BioMarin touts trial win in label expansion bid
With phase 3 results that have “exceeded” BioMarin’s expectations, the California biotech looks set up to gain…
May 25, 2026
ASCO: Merck, Kelun's sac-TMT ADC combo beats Keytruda by 65% on progression in first-line lung cancer
PipelineFiercePharma ↗
ASCO: Merck, Kelun's sac-TMT ADC combo beats Keytruda by 65% on progression in first-line lung cancer
According to an abstract released ahead of the ASCO 2026 annual meeting, combining the TROP2-directed ADC with…
May 24, 2026
AstraZeneca, Daiichi beat Gilead to first-line TNBC with FDA nod for Datroway
PipelineFiercePharma ↗
AstraZeneca, Daiichi beat Gilead to first-line TNBC with FDA nod for Datroway
A three-way battle among TROP2 ADCs in first-line triple-negative breast cancer is forming as AstraZeneca and …
May 23, 2026